Cargando…
Sodium Butyrate Ameliorates Streptozotocin-Induced Type 1 Diabetes in Mice by Inhibiting the HMGB1 Expression
Type 1 diabetes (T1D) is an autoimmune disease characterized by the immune cell-mediated progressive destruction of pancreatic β-cells. High-mobility group box 1 protein (HMGB1) has been recognized as a potential immune mediator to enhance the development of T1D. So we speculated that HMGB1 inhibito...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6209660/ https://www.ncbi.nlm.nih.gov/pubmed/30410469 http://dx.doi.org/10.3389/fendo.2018.00630 |
_version_ | 1783366940737142784 |
---|---|
author | Guo, Yu Xiao, Zheng Wang, Yanan Yao, Weihua Liao, Shun Yu, Bo Zhang, Jianqiang Zhang, Yanxiang Zheng, Bing Ren, Boxu Gong, Quan |
author_facet | Guo, Yu Xiao, Zheng Wang, Yanan Yao, Weihua Liao, Shun Yu, Bo Zhang, Jianqiang Zhang, Yanxiang Zheng, Bing Ren, Boxu Gong, Quan |
author_sort | Guo, Yu |
collection | PubMed |
description | Type 1 diabetes (T1D) is an autoimmune disease characterized by the immune cell-mediated progressive destruction of pancreatic β-cells. High-mobility group box 1 protein (HMGB1) has been recognized as a potential immune mediator to enhance the development of T1D. So we speculated that HMGB1 inhibitors could have anti-diabetic effect. Sodium butyrate is a short fatty acid derivative possessing anti-inflammatory activity by inhibiting HMGB1. In the current study, we evaluated the effects of sodium butyrate in streptozotocin (STZ)-induced T1D mice model. Diabetes was induced by multiple low-dose injections of STZ (40 mg/kg/day for 5 consecutive days), and then sodium butyrate (500 mg/kg/day) was administered by intraperitoneal injection for 7 consecutive days after STZ treatment. Blood glucose, incidence of diabetes, body weight, pancreatic histopathology, the amounts of CD4(+)T cell subsets, IL-1β level in serum and pancreatic expressions levels of HMGB1, and NF-κB p65 protein were analyzed. The results showed that sodium butyrate treatment decreased blood glucose and serum IL-1β, improved the islet morphology and decreased inflammatory cell infiltration, restored the unbalanced Th1/Th2 ratio, and down-regulated Th17 to normal level. In addition, sodium butyrate treatment can inhibit the pancreatic HMGB1 and NF-κB p65 protein expression. Therefore, we proposed that sodium butyrate should ameliorate STZ-induced T1D by down-regulating NF-κB mediated inflammatory signal pathway through inhibiting HMGB1. |
format | Online Article Text |
id | pubmed-6209660 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-62096602018-11-08 Sodium Butyrate Ameliorates Streptozotocin-Induced Type 1 Diabetes in Mice by Inhibiting the HMGB1 Expression Guo, Yu Xiao, Zheng Wang, Yanan Yao, Weihua Liao, Shun Yu, Bo Zhang, Jianqiang Zhang, Yanxiang Zheng, Bing Ren, Boxu Gong, Quan Front Endocrinol (Lausanne) Endocrinology Type 1 diabetes (T1D) is an autoimmune disease characterized by the immune cell-mediated progressive destruction of pancreatic β-cells. High-mobility group box 1 protein (HMGB1) has been recognized as a potential immune mediator to enhance the development of T1D. So we speculated that HMGB1 inhibitors could have anti-diabetic effect. Sodium butyrate is a short fatty acid derivative possessing anti-inflammatory activity by inhibiting HMGB1. In the current study, we evaluated the effects of sodium butyrate in streptozotocin (STZ)-induced T1D mice model. Diabetes was induced by multiple low-dose injections of STZ (40 mg/kg/day for 5 consecutive days), and then sodium butyrate (500 mg/kg/day) was administered by intraperitoneal injection for 7 consecutive days after STZ treatment. Blood glucose, incidence of diabetes, body weight, pancreatic histopathology, the amounts of CD4(+)T cell subsets, IL-1β level in serum and pancreatic expressions levels of HMGB1, and NF-κB p65 protein were analyzed. The results showed that sodium butyrate treatment decreased blood glucose and serum IL-1β, improved the islet morphology and decreased inflammatory cell infiltration, restored the unbalanced Th1/Th2 ratio, and down-regulated Th17 to normal level. In addition, sodium butyrate treatment can inhibit the pancreatic HMGB1 and NF-κB p65 protein expression. Therefore, we proposed that sodium butyrate should ameliorate STZ-induced T1D by down-regulating NF-κB mediated inflammatory signal pathway through inhibiting HMGB1. Frontiers Media S.A. 2018-10-25 /pmc/articles/PMC6209660/ /pubmed/30410469 http://dx.doi.org/10.3389/fendo.2018.00630 Text en Copyright © 2018 Guo, Xiao, Wang, Yao, Liao, Yu, Zhang, Zhang, Zheng, Ren and Gong. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Endocrinology Guo, Yu Xiao, Zheng Wang, Yanan Yao, Weihua Liao, Shun Yu, Bo Zhang, Jianqiang Zhang, Yanxiang Zheng, Bing Ren, Boxu Gong, Quan Sodium Butyrate Ameliorates Streptozotocin-Induced Type 1 Diabetes in Mice by Inhibiting the HMGB1 Expression |
title | Sodium Butyrate Ameliorates Streptozotocin-Induced Type 1 Diabetes in Mice by Inhibiting the HMGB1 Expression |
title_full | Sodium Butyrate Ameliorates Streptozotocin-Induced Type 1 Diabetes in Mice by Inhibiting the HMGB1 Expression |
title_fullStr | Sodium Butyrate Ameliorates Streptozotocin-Induced Type 1 Diabetes in Mice by Inhibiting the HMGB1 Expression |
title_full_unstemmed | Sodium Butyrate Ameliorates Streptozotocin-Induced Type 1 Diabetes in Mice by Inhibiting the HMGB1 Expression |
title_short | Sodium Butyrate Ameliorates Streptozotocin-Induced Type 1 Diabetes in Mice by Inhibiting the HMGB1 Expression |
title_sort | sodium butyrate ameliorates streptozotocin-induced type 1 diabetes in mice by inhibiting the hmgb1 expression |
topic | Endocrinology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6209660/ https://www.ncbi.nlm.nih.gov/pubmed/30410469 http://dx.doi.org/10.3389/fendo.2018.00630 |
work_keys_str_mv | AT guoyu sodiumbutyrateamelioratesstreptozotocininducedtype1diabetesinmicebyinhibitingthehmgb1expression AT xiaozheng sodiumbutyrateamelioratesstreptozotocininducedtype1diabetesinmicebyinhibitingthehmgb1expression AT wangyanan sodiumbutyrateamelioratesstreptozotocininducedtype1diabetesinmicebyinhibitingthehmgb1expression AT yaoweihua sodiumbutyrateamelioratesstreptozotocininducedtype1diabetesinmicebyinhibitingthehmgb1expression AT liaoshun sodiumbutyrateamelioratesstreptozotocininducedtype1diabetesinmicebyinhibitingthehmgb1expression AT yubo sodiumbutyrateamelioratesstreptozotocininducedtype1diabetesinmicebyinhibitingthehmgb1expression AT zhangjianqiang sodiumbutyrateamelioratesstreptozotocininducedtype1diabetesinmicebyinhibitingthehmgb1expression AT zhangyanxiang sodiumbutyrateamelioratesstreptozotocininducedtype1diabetesinmicebyinhibitingthehmgb1expression AT zhengbing sodiumbutyrateamelioratesstreptozotocininducedtype1diabetesinmicebyinhibitingthehmgb1expression AT renboxu sodiumbutyrateamelioratesstreptozotocininducedtype1diabetesinmicebyinhibitingthehmgb1expression AT gongquan sodiumbutyrateamelioratesstreptozotocininducedtype1diabetesinmicebyinhibitingthehmgb1expression |